Navigation Links
Multiple NIH Phase 2 HIV Vaccine Trials Using Vical's Technology Produce Encouraging Results
Date:8/22/2007

SEATTLE, Aug. 22 /PRNewswire-FirstCall/ -- Vical Incorporated (Nasdaq: VICL) announced today that results from a series of HIV vaccine Phase 2a clinical trials, using a plasmid DNA (pDNA) vaccine developed by the NIH Vaccine Research Center and manufactured by Vical, reinforced previously reported Phase 1 conclusions that a "DNA prime-adenoviral vector boost" vaccine regimen was safe and well-tolerated, and was effective in inducing T-cell immune responses in up to 70% of the vaccine recipients.

"These recent vaccine trials contribute to the growing body of knowledge demonstrating plasmid DNA priming as a key factor in achieving significant immune responses against HIV, a particularly difficult target pathogen, bringing us one step closer to evaluating the effectiveness of a prime-boost HIV vaccine regimen in a prophylactic setting," said Vijay B. Samant, Vical's President and Chief Executive Officer. "The latest International AIDS Vaccine Initiative (IAVI) listing of ongoing preventive HIV vaccine clinical trials shows that more than half use pDNA either alone or in combination with other vaccine modalities. We are very pleased that DNA technology is an integral part of the effort to address this high priority global health problem."

The trials involved priming an immune response with three doses of a pDNA vaccine over a two month period, based on Vical's proprietary DNA technology, and boosting the response with a single dose of adenoviral vector vaccine at six months. The three trials, collectively known as TRIAD, were conducted by the National Institute of Allergy and Infectious Diseases (NIAID) HIV Trials Vaccine Network (HVTN), the IAVI, and the U.S. Military HIV Research Program (USMHRP). Richard Koup, M.D., Chief of Immunology at the Dale and Betty Bumpers Vaccine Research Center (VRC), NIAID, National Institutes of Health (NIH), highlighted TRIAD summary results and conclusions in an oral presentation, "Update on safety and immunogenicity
'/>"/>

SOURCE Vical Incorporated
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple Myeloma and Waldenstroms Macroglobulinemia
2. Velcade (Bortezomib) for Injection Based Therapies Produced Complete Remission Rates as High as 54 Percent in Patients With Previously Treated Multiple Myeloma
3. Velcade (bortezomib) for Injection Based Therapies Achieved Survival Rates as High as 100 Percent in Newly Diagnosed Multiple Myeloma Patients
4. Gentiums Defibrotide Seen as Active in Multiple Myeloma
5. ACE-011 Improves Multiple Myeloma Bone Disease in a Preclinical Model
6. New Data from Multiple Studies Show Galvus Delivers Consistent and Robust Blood Sugar Control in Patients with Type 2 Diabetes
7. CytRx Announces Clinical Results from Its Rising Multiple Dose Trial with Arimoclomol for ALS
8. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
9. Velcade (bortezomib) for Injection Survival Data in Front-Line Multiple Myeloma Patients to be Featured at 11th International Myeloma Workshop
10. New Research Demonstrates Broad Efficacy of Azixa (MPC-6827) Against Multiple Tumor Types and in Drug Resistant Cell Lines
11. Orchestra Therapeutics Announces New Phase II Clinical Data on NeuroVax Demonstrating Marked Expansion of Regulatory T Cell Populations in Patients With Multiple Sclerosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... Valeant Pharmaceuticals International, Inc. (NYSE: ... company,s Bridgewater, New Jersey location ... Drug Administration (FDA) relating to an inspection in June ... Aesthetic injectable, which was divested to Galderma S.A. in ... Valeant,s contract manufacturers (rather than Valeant,s own internal manufacturing) ...
(Date:9/30/2014)... MOUNTAIN VIEW, Calif. , Sept. 30, 2014 /PRNewswire/ ... today, which integrates with HealthKit in iOS 8 and ... with their doctors. The app harnesses native iOS technologies ... patients to maintain a robust connection with their doctors ... wearable health devices and the data they collect is ...
(Date:9/30/2014)... Sept. 30, 2014  Based on its recent ... & Sullivan recognizes Ventana Medical Systems, Inc. (Ventana), ... 2014 North American Frost & Sullivan Award for ... along with a focus on innovation and improving ... in tissue-based cancer diagnostic solutions for patients worldwide. ...
Breaking Medicine Technology:Valeant Pharmaceuticals' Bridgewater Location Receives Warning Letter From FDA 2HealthLoop Integrates with Apple's HealthKit Enabling Patients to Share Health Data with Their Doctors Right from their iPhone 2Frost & Sullivan applauds the diversity of Ventana products and services for the cancer diagnostics market 2Frost & Sullivan applauds the diversity of Ventana products and services for the cancer diagnostics market 3Frost & Sullivan applauds the diversity of Ventana products and services for the cancer diagnostics market 4
... Neb., May 15 Creighton Medical Laboratories, based at ... announced today that it has become the first clinical ... testing method for cancer. The method, called SNP array ... to study cancer for several years. However, Creighton Medical ...
... Case Demonstrating RenalGuard To Be PresentedFRANKLIN, Mass., May ... PLCSF), a company focused on innovative cardiac and ... will demonstrate its RenalGuard System(TM) at EuroPCR, the ... Cardiovascular Interventions (EAPCI), May 19-22, 2009, in Barcelona, ...
Cached Medicine Technology:Creighton Medical Laboratories First to Offer New Cancer Test 2Creighton Medical Laboratories First to Offer New Cancer Test 3PLC Medical Systems to Demonstrate RenalGuard(R) at EuroPCR 2009 2PLC Medical Systems to Demonstrate RenalGuard(R) at EuroPCR 2009 3PLC Medical Systems to Demonstrate RenalGuard(R) at EuroPCR 2009 4
(Date:9/30/2014)... Palm Beach, Florida (PRWEB) September 30, 2014 ... the No. 1 selling beauty brand on Amazon.com. , ... Sellers in their respective beauty categories on Amazon.com,” said Craig ... available in the UK on Amazon.co.uk and Canada on Amazon.ca ... latest products, which just launched earlier last month, are already ...
(Date:9/30/2014)... of Dental Medicine have been awarded a $11.8 million, ... Craniofacial Research, part of the National Institutes of Health, ... cleft lip and cleft palate and to expand the ... and Pennsylvania. , Orofacial clefts (OFCs), which are ... form when a baby,s mouth doesn,t develop properly during ...
(Date:9/30/2014)... of Michigan are pleased to announce an agreement to ... and Endocrinology , which is now open for submissions ... 2015. , The journal is led by Editor-in-Chief, ... of Metabolism, Endocrinology, and Diabetes, at the University of ... an international Editorial Board. , Clinical Diabetes ...
(Date:9/30/2014)... as an unusual character from a "Seinfeld" episode or ... genetic disease called SCID, short for severe combined immunodeficiency, ... contact because their bodies, natural defenses are too weak ... than 2,000 new births each year worldwide, SCID is ... a human immunodeficiency virus HIV/AIDS. , Now, using ...
(Date:9/30/2014)... and cardiac muscles contain few stem cells, heart ... heart attack. Now Tel Aviv University researchers are ... tissue engineering. , Dr. Tal Dvir and his ... Biotechnology, Department of Materials Science and Engineering, and ... sophisticated micro- and nanotechnological tools ranging in ...
Breaking Medicine News(10 mins):Health News:OZ Naturals Now the No. 1 Selling Beauty Brand on Amazon.com 2Health News:OZ Naturals Now the No. 1 Selling Beauty Brand on Amazon.com 3Health News:Pitt team searches for genetic roots of cleft lip, palate 2Health News:BioMed Central to publish open access journal in collaboration with the University of Michigan 2Health News:Virginia Tech researchers discover potential biomarker to detect 'bubble boy' disorder 2Health News:Virginia Tech researchers discover potential biomarker to detect 'bubble boy' disorder 3Health News:A heartbeat away? Hybrid 'patch' could replace transplants 2
... Attention Deficit Hyperactivity Disorder, or ADHD, is widely recognized by ... in place. But as many as six percent of all ... Demonstrating a lack of refined motor skills, children with DCD ... staying organized at school. They appear to be uncoordinated ...
... , SUNDAY, April 3 (HealthDay News) -- There,s a ... women, but it depends on their body weight, researchers report. ... smokers who were not obese, but this strong association was ... study. Researchers analyzed data from 76,628 women, aged 50 ...
... test believe it is the most accurate yet in ... asbestos. Study results of this aptamer proteomic technology were ... April 2-6. In a blinded test performed under ... Research Network Biomarker Discovery Lab, the proteomic assay could ...
... NYU Langone Medical Center have investigated a novel protein ... can accurately identify proteins secreted from cancerous tumors caused ... American Association for Cancer Research 102nd Annual Meeting 2011 ... performed under the sponsorship of the National Cancer Institute,s ...
... Amanda Gardner HealthDay Reporter , SUNDAY, April 3 ... a new valve in a damaged heart is as good ... risk of stroke, researchers reported Sunday. Transcatheter ... in the heart via an artery in the leg or ...
... Reporter , SATURDAY, April 2 (HealthDay News) -- Men taking ... the risk of a heart attack or stroke, a small, ... 5 percent increase in the thickness of the large artery ... to the brain, the researchers from Emory University found. ...
Cached Medicine News:Health News:Clumsy kids who don't 'grow out of it' 2Health News:Study Links Smoking, Breast Cancer in Older Women 2Health News:Protein test detects early-stage, asbestos-related pulmonary cancer 2Health News:New test detects early-stage, asbestos-related pulmonary cancer 2Health News:Minimally Invasive Heart-Valve Procedure Shows Promise: Study 2Health News:Minimally Invasive Heart-Valve Procedure Shows Promise: Study 3Health News:Study Hints at Link Between Antidepressants and Heart Trouble 2Health News:Study Hints at Link Between Antidepressants and Heart Trouble 3
... A lower cost alternative to Equalizers, the ... transfers between two different vessel configurations. With the ... can be quickly and easily adjusted for test ... Ergonomic Design for Unparalleled Comfort Pick ...
... The Equalizer With 384 Well Plate ... the revolutionary features of the original Equalizerexpandable and ... autoclavable components, and in-lab calibration capabilities. In addition, ... tips down to 4.5mm for loading and accessing ...
Packaging: Set includes: Eight-channel pipette (10.8 mm with 0.5-5.0 μl capacity) 25 PrismStrip 96 tips with rack 2 FlexPlates with a holder...
The Biopette E has a comfortable, ergonomic design. Fully motorized piston drive. Virtually eliminates pipetting forces. User-friendly operator interface. Simple, precise volume setting. Rechargelabl...
Medicine Products: